Table 1

IFN-γ ELISPOT analysis of NY-ESO-1-specific T cells in peptide-stimulated CD8+ lymphocytes from HLA-A2 melanoma patients

Days after stimulation:Day 7Day 14
Stimulated with peptide:SLLMWITQCSLLMWITQASLLMWITQCSLLMWITQA
Peptide SLLMWITQCa++++
Patient code
LAU 427b5101620343444
LAU 5011716 87 6 152 13 140
LAU 97172718725364837
LAU 15612 45 17 70 16 >200 11 88
LAU 165112010712172414
LAU 19822212718252824 82
LAU 2031016101721235133
LAU 212392512725372518
LAU 23381310724154240
LAU 25315261218412834
  • a The assay was performed as detailed in “Materials and Methods.” Results are reported for 10 HLA-A

  • * 0201 melanoma patients using CD8+-enriched PBMCs stimulated in vitro with either NY-ESO-1 parental peptide 157–165 or the peptide analogue C165A for the indicated time period.

  • b Numbers represent the mean of IFN-γ spot numbers measured in duplicate cultures containing 5 × 104 APCs (T2) and 5 × 104 peptide-stimulated CD8+-enriched T cells. Figures in bold represent significant numbers (three times over background values) obtained in the presence of NY-ESO-1 parental peptide 157–165 in comparison with values obtained in the presence of T2 cells alone.